Drug Database
BE

bevacizumab (Lumiere)

✓ Approved

Laboratorio Elea · VEGFA · Monoclonal Antibodies

What is bevacizumab?

bevacizumab is a monoclonal antibodies developed by Laboratorio Elea. It is approved for therapeutic indications via injectable (others) or intraocular injection.

Drug Profile

Brand NamesLumiere
CompanyLaboratorio Elea
Drug ClassMonoclonal Antibodies, Antibody
Molecular TargetVEGFA
RouteInjectable (Others), Intraocular Injection
StatusApproved
Sources: ClinicalTrials.gov, Laboratorio Elea

Mechanism of Action

Molecular Targets

bevacizumab acts on 1 molecular target:

VEGFAvascular endothelial growth factor A (VPF, MVCD1)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

bevacizumab is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Eye disordersNeovascular age-related macular degeneration✓ Approved

Related Research Articles

PubMedFrontiers in oncology2026-11-11

Dramatic and sustained regression of an inferior vena cava tumor thrombus in a patient with unresectable giant hepatocellular carcinoma following sequential systemic therapy: a case report and literature review.

Hou Ju J, Wu Kun Li KL

Hepatocellular carcinoma (HCC) with major vascular invasion, particularly inferior vena cava (IVC) tumor thrombus, carries a dismal prognosis and has long been considered a treatment challenge. Although immune checkpoint inhibitors (ICIs) combined with anti-angiogenic agents have become the first-line standard systemic therapy for advanced HCC, data on long-term survival in patients with large tumors complicated by IVC tumor thrombus remain scarce. Herein, we report the case of a 63-year-old male patient with Barcelona Clinic Liver Cancer (BCLC) stage B unresectable HCC in whom an IVC tumor thrombus emerged during first-line therapy, with a baseline Child-Pugh score of 7 (class B) and albumin-bilirubin (ALBI) grade 3. The patient received first-line sintilimab plus the bevacizumab biosimilar IBI305 at an individualized 4-week interval for financial reasons. Early in first-line therapy (January 2023) a new IVC filling defect appeared; multidisciplinary review favored improved visualization of a previously occult thrombus over true progression, and treatment was continued. After twelve cycles, therapy was self-discontinued and the patient remained off treatment for 10.5 months, during which he required admission for massive ascites (at month 3) and the tumor later progressed. Regorafenib was then initiated as a non-standard second-line agent at an individualized reduced dose (80 mg/day, later 80 mg every other day for hand-foot skin reaction). The IVC tumor thrombus regressed completely and the target-lesion sum of diameters decreased by 48.9% from baseline, achieving partial response (PR) per RECIST 1.1 by June 2026. As of June 2026, the patient remains alive more than 4 years from initial detection of the liver mass. This case demonstrates that durable long-term survival can be achieved in patients with giant HCC and IVC tumor thrombus through sequential systemic therapy, even in the setting of treatment interruption. This report provides clinical insight for the management of advanced HCC with major vascular invasion.

PMID 43010928
Read full article →
PubMedFrontiers in immunology2026-11-10

Efficacy and safety of sintilimab plus bevacizumab with or without transarterial chemoembolization for unresectable hepatocellular carcinoma: a propensity score-matched retrospective cohort study.

Wang Zizhuo Z, Wu Bailu B, Wu Chunshu C, Wu Hongquan H et al.

To compare the efficacy and safety of transarterial chemoembolization (TACE) plus sintilimab and bevacizumab (triple therapy) versus sintilimab and bevacizumab alone (dual therapy) in unresectable hepatocellular carcinoma (uHCC). This single-center retrospective cohort study enrolled consecutive patients with uHCC who received triple or dual therapy between October 2021 and May 2025. Propensity score matching (PSM) was performed using logistic regression (1:1 nearest-neighbor, caliper: 0.02 SD). The primary endpoint was progression-free survival (PFS). The secondary endpoints included objective response rate (ORR), disease control rate (DCR), overall survival (OS), and safety. An exploratory prognostic score for PFS was developed in the matched cohort and used to define risk strata for hypothesis-generating analyses. After PSM, 40 patients were included in each group. The triple therapy group achieved a longer median PFS than the dual-therapy group (13.11 vs. 8.57 months; log-rank P = 0.026). The median OS was not reached (log-rank P = 0.20). The ORR (75.0% vs. 60.0%; P = 0.233), DCR (95.0% vs. 82.5%; P = 0.154), and radiographic downstaging rate (17.5% vs. 5.0%; P = 0.154) were numerically higher with triple therapy. The prognostic model demonstrated that, median PFS was 14.46 months, 11.50 months, and 5.62 months in the low-, intermediate-, and high-risk groups, respectively (log-rank P < 0.001). Risk-stratified HR estimates were numerically lowest in the intermediate-risk group; however, the formal treatment-by-risk-group interaction was not statistically significant (P for interaction = 0.879). Grade 3-4 adverse events were numerically more frequent with triple therapy (37.5% vs. 22.5%; P = 0.222), with no treatment-related deaths. In PSM-matched uHCC patients, TACE plus sintilimab-bevacizumab was associated with longer PFS, with generally manageable toxicity but a numerically higher incidence of grade 3-4 adverse events. Exploratory risk-stratified analyses generated hypotheses regarding potential differences in treatment benefit across prognostic strata.

PMID 43005167
Read full article →
PubMedAdvanced pharmaceutical bulletin2026-11-10

Development of a Flow Cytometric Immunoassay Using Recombinant Vascular Endothelial Growth Factor (VEGF)-Functionalized Poly(ε-Caprolactone) Microbeads for Bevacizumab Quantification.

Namaei-Ghasemnia Negar N, Rabiee Mohammad M, Davami Fatemeh F, Talebkhan-Garoosi Yeganeh Y et al.

With the growing research interest in therapeutic monoclonal antibodies (mAbs) and their broad range of applications, the development of reliable analytical approaches for their quantification has become increasingly important. Since, microbead (MB)-based flow cytometric immunoassays have emerged as highly sensitive analytical methods, the aim of this study was to develop and evaluate a flow cytometry-based method using poly(ε-caprolactone) (PCL) MBs to quantify bevacizumab (BVZ) concentration. PCL MBs were synthesized through the emulsion/solvent evaporation method and modified by reaction with 1,2-ethylenediamine (EDA) to enable covalent binding of biomolecules. Based on the optimal biomolecule immobilization conditions determined using a model protein, purified recombinant vascular endothelial growth factor (VEGF) protein was immobilized on the surface of amine-functionalized MBs (A-MBs(45)) to capture BVZ, which was then detected using fluorescein isothiocyanate (FITC)-conjugated anti-human IgG antibody in flow cytometry. The synthesized PCL MBs, with an average diameter of 6.62±0.17 µm, were within the suitable particle size range for immunoassay applications. The optimal aminolysis time was found to be 45 min at 37 °C, and the maximum protein coupling was achieved 5 h post-incubation at pH 8.0. The developed MB-based flow cytometric immunoassay demonstrated the potential to quantify BVZ with a limit of detection (LOD) and limit of quantification (LOQ) of about 6.71 and 22.73 ng mL-1, respectively. Considering the ease of fabrication and functionalization of PCL MBs under the obtained optimal conditions, along with their capability for analyte detection, these cost-effective analytical platforms may serve as promising candidates for BVZ quantification.

PMID 43005261
Read full article →
PubMedInternational journal of surgery case reports2026-11-10

Metachronous cutaneous metastasis from right-sided colon cancer at a drain site: a case report and literature review.

Alouani Hazem H, Nasri Salsabil S, Ben Safta Amine A, Samâali Imen I et al.

Cutaneous metastases from colorectal cancer (CRC) are rare and often indicate advanced disease. This case report highlights an uncommon pattern of recurrence from right-sided colon cancer and reviews the pertinent literature. A 57-year-old woman with a history of emergency right colectomy for perforated colonic adenocarcinoma developed a cutaneous nodule, rapidly increasing in size and measuring 3 × 4 cm, at the site of a previous drain 6 months after surgery. Biopsy confirmed metastatic adenocarcinoma. Apart from the cutaneous metastasis, imaging showed a deep retroperitoneal mass that did not communicate with the cutaneous nodule and no other visceral metastases. Systemic chemotherapy was reinitiated with bevacizumab. Due to refractory bleeding and transfusion-dependent anemia, surgical excision of the cutaneous lesion was performed, improving the patient's quality of life. Cutaneous metastases from CRC are unusual and generally associated with poor prognosis. Their management remains palliative in most cases. Drain-site metastasis is particularly rare and may reflect tumor cell seeding. Vigilance for nodular skin lesions in post-operative CRC patients is crucial. Prompt biopsy and imaging facilitate early diagnosis and appropriate management.

PMID 43006016
Read full article →
PubMedJournal of medicine and life2026-11-10

Multistep surgical management in a patient with recurrent laryngeal papillomatosis: a case report and surgical analysis.

Popescu Dan-Alexandru DA, Tudosie Mihai-Dumitru MD, Rujan Simona-Andreea SA, Taher Bianca-Petra BP et al.

Recurrent respiratory papillomatosis (RRP) is a benign yet potentially aggressive disease caused by infection with human papillomavirus (HPV), most commonly types 6 and 11. It is characterized by recurrent papillomatous growth within the respiratory tract, predominantly affecting the larynx and often requiring repeated surgical interventions. We present the case of a 29-year-old man with a history of juvenile-onset RRP who developed persistent, progressive dysphonia and exertional dyspnea. Endoscopic evaluation revealed multifocal laryngeal involvement, including lesions of the epiglottis and arytenoid region. The patient underwent endoscopic CO2 laser excision with initially favorable outcomes; however, early recurrence necessitated a second, more extensive surgical intervention. The postoperative course was satisfactory, with improved airway patency and vocal function. The patient was evaluated for adjuvant therapy with bevacizumab but was not considered eligible. This case highlights the recurrent nature of RRP, the importance of individualized surgical management, and the role of adjuvant therapies in selected cases. Long-term surveillance remains essential to optimize functional outcomes and enable early detection of recurrence.

PMID 43005615
Read full article →
PubMedMedComm2026-11-10

Fruquintinib Plus FOLFIRI/FOLFOX as Second-Line Therapy in Patients With RAS-Mutant Metastatic Colorectal Cancer: A Multicenter, Open-Label, Single-Arm Phase II Study.

Xu Yun Y, Li Cong C, Zeng Yiwei Y, Wu Yuchen Y et al.

For patients with RAS-mutant metastatic colorectal cancer (mCRC), effective second-line therapies remain limited. In this multicenter, single-arm phase II trial conducted from March 2023 to November 2025, we enrolled 42 patients with RAS-mutant mCRC who had progressed after first-line therapy. All patients received fruquintinib (4 mg once daily on Days 1-21 of each 28-day cycle) combined with either FOLFIRI or FOLFOX chemotherapy based on prior treatment history. The median progression-free survival (PFS) was 8.08 months (95% CI: 6.18, 9.46), ranking among the longest reported in the second-line setting. The objective response rate (ORR) was 52.5% (95% CI: 36.13, 68.49) and the disease control (DCR) rate 97.5% (95% CI: 86.84, 99.94). Notably, this study reports the first conversion surgery outcomes in this setting, with three patients (7.14%) undergoing successful resection-a rate approaching that observed in first-line trials. The safety profile was manageable, with 7.1% of patients experiencing grade ≥ 3 adverse events including diarrhea (4.8%) and thrombocytopenia (2.4%); no treatment-related deaths occurred. Prior bevacizumab treatment did not affect the consistent efficacy of this regimen. These results support further randomized evaluation of this fruquintinib-based combination as a promising second-line option for patients with RAS-mutant mCRC.

PMID 43005371
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about bevacizumab